<DOC>
	<DOCNO>NCT01829698</DOCNO>
	<brief_summary>Though ursodeoxycholate acid ( UDCA ) well know effective therapy PBC , clinical effectiveness UDCA may limit poor absorption extensive biotransformation.The hydrophillic bile acid tauroursodeoxycholate ( TUDCA ) active ingredient UDCA , approve state food drug administration China treatment cholesterol stones.So necessary verify efficacy safety TUDCA treatment adult primary biliary cirrhosis . In randomized , double-blinded , double -dummy , parallel-controlled multicenter clinical trial , detect proportion patient AKP decline 25 % primary outcome ; decline ALP , total bilirubin , GGT , ALT AST secondary outcome patient treat TUDCA UDCA 24 week .</brief_summary>
	<brief_title>Efficacy Safety Study TUDCA Compare UDCA Treatment Chronic Cholestatic Liver Disease-PBC</brief_title>
	<detailed_description>This double-blind , randomize , parallel control , multicenter , clinical trial . Subjects inclusion randomization pass screening , continuous administration test drug ( Taurolite ) control drug ( Ursofalk ) treatment 24 week . Compare safety efficacy Taurolite v Ursofalk . At end double-blind period，enroll 100 subject two group randomly , consecutive treatment use TUDCA 24 week . Further evaluate efficacy safety tauroursodeoxycholic acid ( TUDCA ) treatment adult primary biliary cirrhosis ( PBC ) long time one year . Also evaluate regimen 's efficacy safety udca take place TUDCA treatment adult primary biliary cirrhosis ( PBC ) patient use udca treatment 24 week .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 Ages Eligible Study : 18 Years 70 Years 2 Alkaline phosphatase ( ALP ) ≥ 2 time Upper Limits Normal ( ULN ) ; 3 Anti mitochondrial antibody ( AMA ) positive / antimitochondrial antibody subtype M2 ( AMAM2 ) positive ; AMA AMAM2 negative , need liver biopsy confirm pathological change PBC . 1．in 3 month screen receive UDCA , hormone , immunosuppressive therapy ; 2．with extrahepatic biliary obstruction ; 3．accompanied hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection ; 4．laboratory screen examination : 1. hemoglobin ( HB ) : male &lt; 11 g/dL , female &lt; 10 g/dL &lt; g/dL ; 2. total white blood cell ( WBC ) count &lt; 3000/mm3 ; 3. absolute neutrophil count ( ANC ) &lt; 1500/mm3 ; 4. platelet ( PLT ) count &lt; 50000/mm3 ; 5. serum albumin &lt; 3.3g/dL ; 6. alanine aminotransferase ( ALT ) ≥ 10 ULN / aspartate aminotransferase ( AST ) ≥ 10ULN ; 7 . ALT ≥ 5 ULN / AST ≥ 5 ULN immunoglobulin G ( IgG ) ≥ 2ULN ; 8. total bilirubin ( TBil ) ≥ 4 ULN ; 9. prothrombin time ( PT ) prolong ≥ 3 second ( limit reference value base ) PTA ≤ 60 % ; 10. serum creatinine ( Cr ) ≥ 1.5ULN . 5．patients esophageal variceal bleeding , ascites , hepatic encephalopathy evidence hepatic decompensation ; 6．diagnosed liver cancer , suspect liver cancer , AFP &gt; 100ng/ml . As AFP 2 time upper limit normal 100ng/ml , need recheck 2 week , AFP &gt; 100ng/ml include 7．body mass index &gt; 28 ( Kg/m2 ) ; 8．alcohol drug abuser within recent year ; 9．there serious heart , lung , kidney , digestive , nervous , mental disease , autoimmune disease malignant tumor 10．druginduced liver injury ; 11. plan transplant organ transplant ; 12． unable unwilling provide inform consent fails comply test requirement ; 13．pregnant , lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>tudca PBC Cholestasis tauroursodeoxycholic acid taurolite</keyword>
</DOC>